Navigation Links
New Data Published in Circulation Showed an Increase in HDL Cholesterol Levels with ACTOS(R) (pioglitazone HCl)
Date:4/15/2008

DEERFIELD, Ill., April 15 /PRNewswire/ --

What and When

Additional results from the clinical trial CHICAGO (Carotid intima-media tHICkness in Atherosclerosis using pioGlitazOne) published today in Circulation revealed that reduced progression of carotid intima-media thickness (CIMT) with ACTOS(R) (pioglitazone HCl) was associated with increased levels of HDL cholesterol (HDL-C, or "good cholesterol") when compared to glimepiride.

The increased effect on HDL-C levels at 24 weeks is expected to have contributed to the reduction of atherosclerosis progression as measured by CIMT at 72 weeks. These results suggest that suppression of atherosclerosis with pioglitazone therapy is linked to its effect to raise HDL cholesterol. An increase in CIMT, the thickness of the inner lining of a patient's carotid, is an indicator of atherosclerotic burden, a condition which leads to reduced or blocked blood flow and is a surrogate marker for the risk of heart attack and stroke.

CHICAGO examined the effects of ACTOS on measures of the atherosclerotic disease process in patients with type 2 diabetes. The randomized, double-blind, controlled study enrolled 462 patients with type 2 diabetes. Patients were treated with a 15 to 45 mg dose of ACTOS or 1 to 4 mg dose of glimepiride for 72 weeks with evaluation after 6 months.

These data, coupled with the recently presented and published PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) trial, add to the body of cardiovascular data for ACTOS. While not definitive, data from CHICAGO and PERISCOPE, looking at two surrogate markers, have shown a consistent trend toward a reduction of atherosclerotic burden in people living with type 2 diabetes. ACTOS studies, conducted over the past 10 years in more than 16,000 patients, including short- and long-term trials, as well as prospective and observational studies, have shown no evidence that ACTOS is associated with an increased risk of heart attack, stroke, or death.

About ACTOS

ACTOS works by directly targeting insulin resistance, a condition in which the body does not efficiently use the insulin it produces to control blood glucose levels. ACTOS, a prescription medication, is taken once daily as an adjunct to diet and exercise, and is approved for use for type 2 diabetes as monotherapy to lower blood glucose and in combination therapy with insulin, sulfonylureas, or metformin.

Additional Information

ACTOS is not for everyone. Certain patients with heart failure should not start taking ACTOS. ACTOS can cause or worsen congestive heart failure. Talk to your doctor immediately if you experience rapid weight gain, fluid retention, or shortness of breath.

Do not take ACTOS if you have active liver disease. Your doctor should perform a blood test to check for liver problems before you start ACTOS and periodically thereafter. Talk to your doctor immediately if you experience nausea, vomiting, stomach pain, tiredness, loss of appetite, dark urine, or yellowing of the skin. If you are of childbearing age, talk to your doctor before taking ACTOS, as it could increase your chance of becoming pregnant. Some people taking ACTOS may experience flulike symptoms, mild-to-moderate swelling of legs and ankles, and anemia. Some people, particularly women, are at higher risk of having bone fractures while taking ACTOS. When taking ACTOS with insulin or sulfonylureas, you may be at risk for low blood sugar. Patients with diabetes should have regular eye exams. If you experience vision problems, consult your doctor immediately. Very rarely, some patients have experienced visual changes while taking ACTOS.

Please visit the ACTOS Web site at http://www.actos.com for Complete Prescribing Information.

Takeda Pharmaceuticals North America, Inc.

Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets oral diabetes, insomnia, and gastroenterology treatments, and through the Takeda Global Research & Development Center, Inc., the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease, and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com.

ACTOS(R) (pioglitazone HCl) is a registered trademark of Takeda Pharmaceutical Company Limited and used under license by Takeda Pharmaceuticals North America, Inc.


'/>"/>
SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CyberKnife Prostate Cancer Planning Study Published in Leading Radiation Oncology Journal
2. Accurate Identification of Tumor Origin Using MicroRNAs is Published by Rosetta Genomics Scientists and Collaborators in Nature Biotechnology
3. Complete ANX-530 Safety Data to be Published in the 2008 Proceedings of the American Society of Clinical Oncology
4. Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
5. WHI Findings Published in JAMA Do Not Affect Clinical Guidance for the Appropriate Use of Hormone Therapy
6. Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology
7. Newly Published EPA RCRA Method 6800 Supports AIT Technology
8. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
9. Vasogens Research Published in European Journal of Neuroscience
10. In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement:
11. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/14/2017)... Portland, Oregon (PRWEB) , ... August 14, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... hardware. , SYZYGY is intended to satisfy the need for a compact, low ...
(Date:8/11/2017)... ... , ... Algenist continues to disrupt the skincare industry with today’s debut of ... Collagen is the key structural element skin needs to maintain its youthful appearance and ... First to market with proprietary collagen water active , ...
(Date:8/10/2017)... Yorba Linda, Ca (PRWEB) , ... August 09, ... ... and exosomes for regenerative medicine applications in the clinic is here. The team ... secreted EVs present in conditioned medium for clinical studies. , Dr. Travis ...
(Date:8/10/2017)... UK (PRWEB) , ... August 10, 2017 , ... ... a new educational webinar to demonstrate how Good Clinical Practice (GCP) can ... site documents. In addition the webinar will discuss the importance of GCP compliance, how ...
Breaking Biology Technology:
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:4/24/2017)... 24, 2017 Janice Kephart , ... Identity Strategy Partners, LLP (IdSP) , today issues ... President Trump,s March 6, 2017 Executive Order: ... vetting can be instilled with greater confidence, enabling ... all refugee applications are suspended by until at ...
(Date:4/13/2017)... -- According to a new market research report "Consumer IAM ... and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global ... grow from USD 14.30 Billion in 2017 to USD 31.75 Billion by ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):